BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38022548)

  • 1. Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells.
    Zheng R; Chen Y; Zhang Y; Liang S; Zhao X; Wang Y; Wang P; Meng R; Yang A; Yan B
    Front Immunol; 2023; 14():1258156. PubMed ID: 38022548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fully human antibody V
    Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.
    Lam N; Trinklein ND; Buelow B; Patterson GH; Ojha N; Kochenderfer JN
    Nat Commun; 2020 Jan; 11(1):283. PubMed ID: 31941907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
    Fujiwara K; Masutani M; Tachibana M; Okada N
    Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 11. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
    Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation.
    McComb S; Nguyen T; Shepherd A; Henry KA; Bloemberg D; Marcil A; Maclean S; Zafer A; Gilbert R; Gadoury C; Pon RA; Sulea T; Zhu Q; Weeratna RD
    Front Immunol; 2022; 13():864868. PubMed ID: 35935988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
    Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
    Front Immunol; 2018; 9():2231. PubMed ID: 30364107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity.
    Vander Mause ER; Atanackovic D; Lim CS; Luetkens T
    Trends Biotechnol; 2022 Jul; 40(7):875-890. PubMed ID: 35078657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
    Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
    Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy.
    Duan Y; Chen R; Huang Y; Meng X; Chen J; Liao C; Tang Y; Zhou C; Gao X; Sun J
    Cell Mol Life Sci; 2021 Dec; 79(1):14. PubMed ID: 34966954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections.
    Olbrich H; Theobald SJ; Slabik C; Gerasch L; Schneider A; Mach M; Shum T; Mamonkin M; Stripecke R
    Hum Gene Ther; 2020 Apr; 31(7-8):423-439. PubMed ID: 32159399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.